The good news just keeps coming for Regeneron Pharmaceuticals
First Eylea was recommended for approval in patients with wet age-related macular degeneration by the Committee for Medicinal Products for Human Use. That's essentially an approval in Europe since the final step is just a rubber stamp by the European Commission.
And then the Food and Drug Administration approved Eylea to treat macular edema following central retinal vein occlusion.
Neither was unexpected. Eylea is already approved in the U.S. for treating wet age-related macular degeneration, so the approval in Europe was widely expected. And the phase 3 trials used to support the expanded approval produced solid results. Roche's rival drug Lucentis is already approved to treat macular edema following central retinal vein occlusion.
The results were so widely expected that shares fell slightly on the combined news on Friday.
That valuation is the only downside to Regeneron I see at the moment. The company sports a market cap of $13.7 billion, which puts it trading at around 18 times expected sales of Eylea this year.
Regeneron needs to accelerate sales of Eylea to grow into that P/S ratio because its other drugs aren't going to help out much. Regeneron's first approved drug, Arcalyst, competes for a very limited number of patients with Novartis'
The new approvals should help increase sales, but with sky-high expectations, investors should be careful investing even if the biotech seems to be able to deliver nothing but good news.
Here's some more good news: You've got a distinct advantage over Wall Street. Find out what it is and how to profit from it in the Fool's new free report "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice." Get your copy absolutely free by clicking here now.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.